Company Profile
Delcath Systems Stock Price, News & Catalysts
- Ticker:
- DCTH
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
19.24 USD (-2.34%)
Close
Last updated: November 19, 2026
364M USD
Market cap
Why the stock is moving
As of Nov 19, 2026, DCTH closed down 2.34% at $19.24. No new same-company headline was identified in the current news window.
Company overview
Interventional Oncology
Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers. Its technology isolates hepatic circulation so high-dose chemotherapy can be delivered to the liver while limiting systemic exposure.
HEPZATO KIT
HEPZATO KIT combines melphalan with the company's percutaneous hepatic-perfusion system. It is approved in the United States for selected adults with unresectable hepatic-dominant metastatic uveal melanoma.
European CHEMOSAT Platform
CHEMOSAT is the European commercial version of Delcath's hepatic-delivery platform. The company supports adoption through treatment-center activation, clinician training, and procedure-based consumable sales.
Pipeline Expansion
Delcath is expanding the platform through the DELUMA study in liver-dominant metastatic breast cancer and through planned development in cholangiocarcinoma and with an oxaliplatin-based perfusion product.
Future catalysts
- IND submission for a HEPZATO development program in cholangiocarcinoma in early 2027.
- Completion of preclinical development for an oxaliplatin-based percutaneous hepatic perfusion product by mid-2027, pending FDA agreement.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Delcath Systems (DCTH)?
Delcath Systems (DCTH) most recently closed at 19.24 USD, a -2.34% move versus the previous session.
What is the market cap of Delcath Systems (DCTH)?
Delcath Systems currently has a market capitalization of 364M USD on BioPharmSignal.
What does Delcath Systems do?
Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers. Its technology isolates hepatic circulation so high-dose chemotherapy can be delivered to the liver while limiting systemic exposure. HEPZATO KIT HEPZATO KIT combines melphalan with the company's percutaneous hepatic-perfusion system. It is...
On which exchange is DCTH stock listed?
Delcath Systems (DCTH) is associated with NASDAQ, United States, Biopharma.
What is Interventional?
Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers.
Which conditions is Delcath Systems targeting with Interventional?
Delcath Systems is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Delcath Systems describe recent progress with Interventional?
IND submission for a HEPZATO development program in cholangiocarcinoma in early 2027. Completion of preclinical development for an oxaliplatin-based percutaneous hepatic perfusion product by mid-2027, pending FDA agreement.
What is Oncology?
Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers.
